Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DCTH vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DCTH Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

DCTH Overall Winner 6-Pillar Tally: DCTH 6 – 0 VVOS Matrix Metrics: DCTH 8 – 2 VVOS

As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Composite vs. Pillar Nuance: While VVOS currently prints a higher short-term Unified Composite Score (36.4/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -107.9% operating margin) and revenue trajectory (+70.7% vs. +34.9% YoY).
  • Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (35.2/100 SELL) and VVOS (36.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: DCTH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.6); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DCTH vs VVOS
DCTH NASDAQ Head-to-Head Winner
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$18.79
-2.34% 1D
Market Cap $669.3M
TTM Revenue $110M
Forward P/E 69.0x
Beta / 30D Vol 1.57β · 130% Vol
Unified Composite Score
35.2 / 100 SELL
Tech 50.0 Fund 36.0 Flow 70.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.0% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $17.34 · SMA50: $16.22
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (DCTH 6 – 0 VVOS)

Columns: Metric · DCTH · VVOS
1. Valuation Multiples DCTH
Forward P/E 69.0x N/M
Trailing P/E 120.2x N/M
PEG Ratio 1.60x N/M
EV / Revenue 5.6x 0.1x
2. Growth & Scale DCTH
Revenue Growth (YoY) +70.7% +34.9%
Earnings Growth (YoY) +750.0% +0.0%
TTM Revenue (USD) $110M $21M
Market Cap $669.3M $1.9M
3. Profitability & Quality DCTH
Gross Margin 87.6% 61.9%
Operating Margin 5.2% -107.9%
Net Profit Margin 6.0% -121.8%
Return on Equity (ROE) 5.4% -8585.3%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M -$21M EBITDA
Cash Flow Margin 18.3% -99.3% EBITDA Mgn
Net Cash / Leverage $53M Net Cash -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DCTH
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 64.8% (26th %ile) N/A (N/A)
Put/Call OI Skew 0.22x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 82.4% of Rev ($91M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DCTH (8) vs VVOS (2)
Institutional Metric DCTH VVOS Criterion Row Edge
Market Capitalization
Scale
$669.3M $1.9M Larger Scale DCTH
Trailing P/E Ratio
Valuation
120.2x N/M Lower Multiple DCTH
Forward P/E Ratio
Valuation
69.0x N/M Lower Multiple DCTH
Revenue Growth (YoY)
Growth
+70.7% +34.9% Higher Growth DCTH
Operating Margin (TTM)
Profitability
5.2% -107.9% Higher Margin DCTH
Net Profit Margin
Profitability
6.0% -121.8% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
5.4% -8585.3% Higher ROE DCTH
52-Week Range Position
Momentum
74% ($8–$23) 0% ($0–$3) Stronger Trend DCTH
Beta / 30D Volatility
Risk Regime
1.57β · 130% Vol 1.70β · 111% Vol Lower Realized Risk VVOS
Unified Institutional Score
Composite Signal
35.2 / 100 (SELL) 36.4 / 100 (SELL) Higher Composite VVOS
Trailing 12M Revenue (USD)
Operating Scale
$110M $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.6% 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.60x PEG · 5.6x EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($53M Net Cash) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DCTH +86.64 pp
DCTH: +27.39% · VVOS: -59.25%
3M Horizon DCTH +92.67 pp
DCTH: +12.18% · VVOS: -80.49%
6M Horizon DCTH +161.66 pp
DCTH: +70.51% · VVOS: -91.15%
1Y Horizon DCTH +218.51 pp
DCTH: +120.8% · VVOS: -97.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DCTH Revenue VVOS Revenue DCTH Op. Margin VVOS Op. Margin Margin Leader
FY2015 $0M N/A -870.6% N/A DCTH
FY2019 N/A $10M N/A -92.8% VVOS
FY2020 N/A $10M N/A -92.1% VVOS
FY2021 $0M $20M -690.0% -120.7% VVOS
FY2022 $0M $20M -1245.1% -156.2% VVOS
FY2023 $0M $10M -1849.0% -125.3% VVOS
FY2024 $40M $20M -33.4% -74.3% DCTH
FY2025 $90M $20M 0.8% -114.1% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DCTH CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 64.8%
IV Percentile 26th %ile
Put/Call OI Skew 0.22x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $669.3M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DCTH vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, Delcath Systems Inc (DCTH) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DCTH carries a Unified Composite Score of 35.2/100 (SELL) at $18.79 (69.0x Forward P/E, 5.2% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin). Composite vs. Pillar Nuance: While VVOS currently prints a higher short-term Unified Composite Score (36.4/100 SELL vs. DCTH 35.2/100 SELL), DCTH captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (5.2% vs. -107.9% operating margin) and revenue trajectory (+70.7% vs. +34.9% YoY). Defensive Composite Rating Caution: Although DCTH compares more favorably head-to-head, both DCTH (35.2/100 SELL) and VVOS (36.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: DCTH trades in a Markup technical trend (CONSOLIDATION options phase, RSI 57.6); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), DCTH cumulative revenue shifted +125.0% while VVOS shifted +100.0%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

DCTH screens cheaper on headline valuation multiples. DCTH trades at 69.0x Forward P/E, 120.2x Trailing P/E, 1.60x PEG, and 5.6x EV/Revenue (18.3% FCF margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, DCTH carries 64.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.22x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.57β · 130% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.